300294.SZ
博雅生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.43
−4.94%Aug 21, 2026, 08:39 UTC
Boyaa Bio-Pharmaceutical announced its first-half 2026 results: revenue of 644 million yuan, down 36.14% year-on-year; net profit attributable to shareholders of 51.19 million yuan, down 77.28% year-on-year.
Source:Aug 6, 2026, 07:46 UTC
Boyaa Bio's controlled subsidiary Dalateqi Boyaa Plasma Collection Co., Ltd. obtained a plasma collection license from the Health Commission of Inner Mongolia Autonomous Region, valid from July 17, 2026 to July 16, 2028.
Source:Jul 20, 2026, 07:45 UTC
China's National Medical Products Administration approved a clinical trial for Boya Bio's human von Willebrand factor product.
Source: